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Abstract
Background: Given the broad definition of an acute exacerbation of IPF, it is likely that acute exacerbations are
heterogeneous in their aetiology, severity and clinical course. We used pooled data from the INPULSIS® trials of
nintedanib versus placebo to investigate whether acute exacerbations reported as serious adverse events were
associated with higher mortality than those reported as non-serious adverse events and to assess the effect of
nintedanib on these types of events.
Methods: Adverse events considered by an investigator to be an acute exacerbation were adjudicated as a
confirmed acute exacerbation, suspected acute exacerbation, or not an acute exacerbation. Time to first
investigator-reported acute exacerbation or confirmed/suspected acute exacerbation reported as a serious adverse
event or non-serious adverse event over the 52-week treatment period was assessed post-hoc. Deaths were
assessed based on data collected over the 52-week treatment period.
Results: Of 63 patients who had ≥1 investigator-reported acute exacerbation, 48 (76.2%) had a first acute
exacerbation reported as a serious adverse event. Thirty-six (3.4%) patients had ≥1 confirmed/suspected acute
exacerbation, of whom 31 had a first event reported as a serious adverse event. Investigator-reported acute
exacerbations reported as serious adverse events occurred in 23 patients in the nintedanib group and 26 in the
placebo group. Confirmed/suspected acute exacerbations reported as serious adverse events occurred in 10 and 21
patients in these groups, respectively. Nintedanib significantly reduced the risk of a first acute exacerbation reported
as a serious adverse event (HR 0.57 [95% CI: 0.32, 0.99]; p = 0.0476) and the risk of a first confirmed/suspected acute
exacerbation reported as a serious adverse event (HR 0.30 [95% CI: 0.14, 0.64]; p = 0.0019) versus placebo. A higher
proportion of patients with investigator-reported acute exacerbations reported as serious adverse events died than
patients with acute exacerbations reported as non-serious adverse events (61.2% versus 7.1%).
Conclusion: Different severities of acute exacerbation of IPF may exist. Acute exacerbations reported as serious
adverse events in the INPULSIS® trials were associated with high mortality. Nintedanib significantly reduced the risk
of acute exacerbations reported as serious adverse events.
Trial registration: ClinicalTrials.gov NCT01335464 and NCT01335477.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic pro-
gressive fibrosing interstitial lung disease characterised
by loss of lung function [1]. IPF has a variable and
unpredictable clinical course [2]. Many patients ex-
perience acute deteriorations in lung function known
as acute exacerbations, which are associated with very
high morbidity and mortality [3]. A perspective pub-
lished by an international group of experts in 2007
defined acute exacerbations of IPF as acute deteriora-
tions in respiratory symptoms associated with changes
in radiographical appearance and the absence of an
identifiable cause [4]. In 2016, an international work-
ing group proposed that the requirement for an event
to be idiopathic be removed from the definition of an
acute exacerbation of IPF based on recognition that
there is little clinical or biological rationale for distin-
guishing idiopathic from non-idiopathic events [3].
The reported frequency of acute exacerbations in pa-
tients with IPF varies widely depending on the method-
ology used. In clinical trials conducted in patients with
IPF and mild to moderate impairment in lung function
at baseline, acute exacerbations were reported in 2 to
16% of placebo-treated patients over 24 to 60 weeks [5–
17]. Similar or slightly higher frequencies of acute exac-
erbations have been observed in contemporary cohort
studies [18–21].
Given the broad definition of an acute exacerbation
of IPF, it is likely that events classified as acute exac-
erbations of IPF are heterogeneous in their aetiology,
severity, and clinical course. A clinical trial, in which
adverse event reporting rules provide a definition for
a serious adverse event, represents an opportunity to
assess the clinical impact of acute exacerbations based
on their seriousness. In this analysis, we used data
from the Phase III INPULSIS® trials of nintedanib in
patients with IPF to investigate whether acute exacer-
bations reported as serious adverse events were asso-
ciated with higher mortality than events reported as
non-serious adverse events and to assess the effect of
nintedanib on these events.
Methods
The design of the two replicate INPULSIS® trials has
been described [17]. Briefly, patients aged ≥40 years with
a diagnosis of IPF within the previous 5 years, forced
vital capacity (FVC) ≥50% predicted, diffusing capacity
of the lung for carbon monoxide (DLco) 30–79% pre-
dicted and a forced expiratory volume in 1 s/FVC ratio ≥
0.7 were randomised 3:2 to receive nintedanib 150 mg
twice daily or placebo for 52 weeks, with a follow-up
visit 4 weeks after the last dose of trial medication. The
primary endpoint was the annual rate of decline in FVC
(mL/year). Time to first investigator-reported acute
exacerbation over the 52-week treatment period was a
key secondary endpoint. Acute exacerbations were de-
fined in the trial protocol as events meeting all of the
following criteria: worsening/development of dyspnoea
within 30 days; new diffuse pulmonary infiltrates on
chest X-ray and/or high-resolution computed tomog-
raphy parenchymal abnormalities with no pneumothorax
or pleural effusion (new ground-glass opacities) since
last visit; and exclusion of known causes of acute wors-
ening, including infection, left heart failure, and pulmon-
ary embolism, as per routine clinical practice and
microbiological studies. Adverse events considered by an
investigator to be acute exacerbations were adjudicated
by a committee of three experts blinded to treatment as-
signment as a confirmed acute exacerbation (if all
protocol-defined criteria were met), a suspected acute
exacerbation (if the event was felt to be an acute exacer-
bation but did not meet all protocol-specified criteria),
or not an acute exacerbation (if an alternative cause was
identified) [22].
Adverse events were reported by the investigators
from randomisation to 4 weeks after the last dose of trial
medication. Serious adverse events were defined as
events that resulted in death, were immediately
life-threatening, resulted in persistent or clinically sig-
nificant disability/incapacity, required/prolonged hospi-
talisation, were related to a congenital anomaly or birth
defect, or were deemed serious for any other reason.
We conducted a post-hoc analysis of time to first acute
exacerbation reported as a serious adverse event or
non-serious adverse event over the 52-week treatment
period using pooled data from both INPULSIS® trials.
Hazard ratios (HR) and two-sided p-values were calcu-
lated using Cox’s regression models with terms for trial,
treatment, sex, age, height. Baseline characteristics of pa-
tients with ≥1 investigator-reported acute exacerbation
reported as a serious adverse event versus patients who
did not have an acute exacerbation were compared using
t-test (continuous variables) or chi-square test (categor-
ical variables). Deaths were based on data collected over
the 52-week treatment period.
Results
A total of 1061 patients were treated in the INPULSIS®
trials (638 with nintedanib, 423 with placebo). At base-
line, mean FVC was 80% predicted and mean DLco was
47% predicted. The majority of patients were male (79%)
and former smokers (68%).
Over 52 weeks, 63 (5.9%) patients had ≥1
investigator-reported acute exacerbation, of whom 48
(76.2%) had a first acute exacerbation reported as a ser-
ious adverse event (Table 1). Of these 48 events, 20 had
fatality noted as the reason for the event being regarded
as a serious adverse event. One patient had an acute
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exacerbation reported as a non-serious adverse event
followed by an acute exacerbation reported as a serious
adverse event; in subsequent analyses, this patient was
classified according to his worse event. Thirty-six (3.4%)
patients had ≥1 adjudicated confirmed/suspected acute
exacerbation, of whom 31 had a first event reported as a
serious adverse event. Twenty-seven (2.5%) patients had
an acute respiratory worsening adjudicated as not an
acute exacerbation, of whom 18 had a first event re-
ported as a serious adverse event.
Patients with ≥1 investigator-reported acute exacerba-
tion reported as a serious adverse event had significantly
lower FVC and DLco and higher (worse) St George’s Re-
spiratory Questionnaire (SGRQ) total score, composite
physiological index and Gender-Age-Physiology (GAP)
stage at baseline than patients who did not have an
investigator-reported acute exacerbation (Table 2).
Deaths occurred in a higher proportion of patients
with investigator-reported acute exacerbations reported
as serious adverse events (n = 30, 61.2%) than patients
with acute exacerbations reported as non-serious
Table 1 Acute exacerbations in the INPULSIS® trials
Adjudication result
Confirmed/
suspected
acute
exacerbation
Not an
acute
exacerbation
Total
Adverse event category
Serious adverse event 31 18 49*
Non-serious adverse event 5 9 14*
Total 36 27 63
*One patient had an acute exacerbation reported as a non-serious adverse
event followed by an acute exacerbation reported as a serious adverse event.
In subsequent analyses, this patient was classified according to his
worse event
Table 2 Baseline characteristics by acute exacerbation reported in INPULSIS® trials (mean ± SD or n %)
Patients who did
not have an acute
exacerbation (n =
998)
Patients who had ≥1
acute exacerbation
reported as a serious
adverse event (n = 49)
Patients who had ≥1 acute
exacerbation but none
reported as a serious adverse
event (n = 14)
p value for patients who did not have an
acute exacerbation vs patients who had ≥1
acute exacerbation reported as a serious
adverse event
Male 789 (79.1) 43 (87.8) 9 (64.3) n.s.
Age, years 66.6 ± 8.0 69.1 ± 7.8 69.8 ± 6.7 n.s.
Body mass index, kg/
m2
28.0 ± 4.6 27.0 ± 4.1 27.2 ± 4.2 n.s.
Ex/current smoker 717 (71.8) 39 (79.6) 9 (64.3) n.s.
Centrilobular
emphysema*
401 (40.2) 17 (34.7) 2 (14.3) n.s.
Time since diagnosis,
years
1.6 ± 1.3 1.8 ± 1.5 1.9 ± 1.3 n.s.
FVC, mL 2746 ± 780 2372 ± 628 2057 ± 549 0.001
FVC, % predicted 80.2 ± 17.8 71.5 ± 15.9 62.0 ± 7.9 0.0008
Diffusing capacity of
the lung for carbon
monoxide†, mmol/
min/kPa
3.9 ± 1.2 3.4 ± 1.3 3.3 ± 1.0 0.0074
St. George’s
Respiratory
Questionnaire total
score
38.9 ± 18.8 50.6 ± 17.9 45.3 ± 18.2 < 0.0001
Composite
physiological index‡
45.7 ± 10.8 51.3 ± 11.8 54.9 ± 8.3 0.0004
GAP score§ 3.5 ± 1.3 4.2 ± 1.3 4.6 ± 1.0 0.0002
HRCT assessment‖
Criteria A, B and C
met
432 (43.3) 25 (51.0) 6 (42.9) n.s.
Criteria A and C
met
99 (9.9) 5 (10.2) 0 (0.0) n.s.
Criteria B and C
met
442 (44.3) 19 (38.8) 7 (50.0) n.s.
*Based on qualitative assessment of HRCT scans, centrally reviewed by a single radiologist. †Haemoglobin-corrected. ‡As described in [28]. §As described in [29].
‖A: definite honeycomb lung destruction with basal and peripheral predominance; B: presence of reticular abnormality and traction bronchiectasis consistent with
fibrosis with basal and peripheral predominance; C: absence of atypical features, specifically nodules and consolidation, with ground glass opacity, if present, less
extensive than reticular opacity pattern. n.s., not significant
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adverse events (n = 1; 7.1%) or patients who did not have
an acute exacerbation (n = 43; 4.3%). There was a signifi-
cant difference in the risk of death between patients with
acute exacerbations reported as serious adverse events
and patients who did not have an acute exacerbation
(HR 53.6 [95% CI: 32.1, 89.5]; p < 0.001) and a numer-
ical, but not statistically significant, difference in the risk
of death between patients with acute exacerbations re-
ported as non-serious adverse events and patients who
did not have an acute exacerbation (HR 3.7 [95% CI: 0.5,
27.2]; p = 0.1962) (Fig. 1).
Investigator-reported acute exacerbations reported
as serious adverse events occurred in 23 (3.6%) versus
26 (6.1%) patients in the nintedanib and placebo
groups, respectively. Of these patients, 13 (56.5%) in
the nintedanib group and 17 (65.4%) in the placebo
group died. Investigator-reported acute exacerbations
reported as non-serious adverse events occurred in 8
(1.3%) versus 6 (1.4%) patients in the nintedanib and
placebo groups, respectively. Of these, no patients in
the nintedanib group and 1 patient in the placebo
group died.
Confirmed/suspected acute exacerbations reported as
serious adverse events occurred in 10 (1.6%) versus 21
(5.0%) patients in the nintedanib and placebo groups, re-
spectively. Of these patients, 5 (50.0%) in the nintedanib
group and 14 (66.7%) in the placebo group died. Con-
firmed/suspected acute exacerbations reported as
non-serious adverse events occurred in 2 (0.3%) versus 3
(0.7%) patients in the nintedanib and placebo groups, re-
spectively. Of these, no patients in the nintedanib group
and 1 patient in the placebo group died.
Compared to placebo, nintedanib significantly reduced
the risk of a first acute exacerbation reported as a ser-
ious adverse event (HR 0.57 [95% CI: 0.32, 0.99]; p =
0.0476) and the risk of a first confirmed/suspected acute
exacerbation reported as a serious adverse event (HR
0.30 [95% CI: 0.14, 0.64]; p = 0.0019) (Fig. 2).
Discussion
Acute exacerbations in patients with IPF are known to
be associated with high mortality [3]. A retrospective re-
view of clinical records from 553 patients with IPF in
Japan from 2003 to 2007 found that acute exacerbation
was the cause of death in 40% of patients [23]. Previous
analyses of data from the INPULSIS® trials have shown
that the mortality rate following an investigator-reported
acute exacerbation in placebo-treated patients was 40%
Fig. 1 Time to death since onset of first investigator-reported acute exacerbation reported as a serious adverse event, first acute exacerbation reported
as a non-serious adverse event, and in patients with no acute exacerbation. Thirteen patients with no acute exacerbation died beyond day 372
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after 30 days and 57% after 180 days and that mortality
following investigator-reported acute exacerbations and
adjudicated confirmed/suspected acute exacerbations
was similar [22]. In these new analyses, we demonstrated
that acute exacerbations reported as serious adverse
events are, regardless of adjudication, associated with
particularly high mortality, with 61% of patients who
had such an event dying within the 52-week treatment
period. This suggests that while all acute exacerbations
are clinically significant events, some types of acute
exacerbations, possibly those with specific aetiologies or
those that affect patients with certain clinical character-
istics, might have a particularly adverse impact on
prognosis.
Patients who had acute exacerbations reported as
serious adverse events had more severe functional im-
pairment at baseline than patients who did not have
an acute exacerbation. This is in line with previous
analyses of risk factors for acute exacerbations, which
have consistently found a higher rate of acute
Fig. 2 Time to (a) first investigator-reported and (b) adjudicated confirmed or suspected acute exacerbation reported as a serious adverse event
in patients treated with nintedanib or placebo
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exacerbations in patients with lower FVC at baseline
[21, 22, 24, 25], and supports the concept of acute
exacerbations as clinical events triggered by injury or
stress to the lung that are more likely to manifest in
patients with advanced disease [3].
Nintedanib is an intracellular inhibitor of tyrosine ki-
nases that has been shown to inhibit processes funda-
mental to the pathogenesis of IPF [26]. In clinical trials,
nintedanib reduced disease progression in patients with
IPF by reducing the rate of decline in FVC by about
50%, irrespective of FVC at baseline [16, 17, 27]. Pooled
data from the INPULSIS® trials showed that
investigator-reported acute exacerbations were reported
in 4.9 and 7.6% of patients treated with nintedanib and
placebo, respectively (HR 0.64 [95% CI: 0.39, 1.05]; p =
0.08) and confirmed/suspected acute exacerbations in
1.9 and 5.7% of patients treated with nintedanib and pla-
cebo, respectively (HR 0.32 [95% CI: 0.16, 0.65]; p =
0.001) [17]. A further post-hoc analysis suggested that
mortality following investigator-reported acute exacerba-
tions and confirmed/suspected acute exacerbations was
lower in patients treated with nintedanib than placebo
(HR 0.56 [95% CI: 0.28, 1.11]; p = 0.092 and HR 0.57
[95% CI: 0.22, 1.48; p = 0.24, respectively) [22].
Limitations of our analyses include their post-hoc na-
ture, the small number of events, and the fact that
events that resulted in death should, by definition, have
been reported as serious adverse events. We were unable
to determine the reasons why some events that were re-
ported as acute exacerbations were not reported as ser-
ious adverse events, particularly when all events that
resulted in hospitalization were to be reported as serious
adverse events. Although acute exacerbations that were
reported as serious adverse events were associated with
particularly high mortality, it is unknown whether these
events were also associated with other indicators of se-
verity such as treatment in intensive care.
Conclusions
Our analysis of data from the Phase III INPULSIS® trials
of nintedanib in patients with IPF showed that acute ex-
acerbations reported as serious adverse events were as-
sociated with higher mortality than events reported as
non-serious adverse events. Nintedanib significantly re-
duced the risk of acute exacerbations reported as serious
adverse events. Further research is needed into the
causes of acute exacerbations in patients with IPF and
how their risk and impact can be reduced. A severity
grading might aid clinicians in making decisions about
how to manage acute exacerbations in patients with IPF.
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